{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}],"title":"Liver"},{"categories":[{"measurements":[{"groupId":"OG000","value":"70"}]}],"title":"Gastrointestinal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Genito-Urinary"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Cardiopulmonary"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Neurologic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Skin"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"The incidence of non-hematological toxicities (Common Terminology Criteria for Adverse Events (CTCAE) 3.0) from initiation of conditioning to Day + 30 or toxicities after day +30, possibly, probably or definitely related to conditioning for all patients treated with Clofarabine (independent of dose level).","groups":[{"description":"Experimental: Clo/BU4","id":"OG000","title":"Clo/Bu4"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"two years","title":"Regimen Related Toxicities","type":"PRIMARY","unitOfMeasure":"toxicities"}